BioStem Technologies Secures U.S. and European Patents for Placental Allografts

BioStem Technologies has been granted four Notices of Allowance by the USPTO for new U.S. design patents focused on fenestrated human placental allografts. Additionally, a European patent has been issued for sterile human placental allografts, featuring proprietary manufacturing methods that enhance growth factor retention.

The patented designs improve fluid management and handling during clinical applications, aiming to optimize healing outcomes in wound care and surgical procedures. BioStem's patent portfolio now includes over 70 patents, reinforcing its strategic positioning in the regenerative medicine sector. The advancements may lead to increased adoption among clinicians, potentially influencing market dynamics in tissue regeneration.